Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II durvalumab multimodality treatment trial in resectable stage III NSCLC
2019-000058-77Phase 2Active
- Sponsor
- Universitätsmedizin Essen
- Start
- Aug 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Progression-free survival rate. Started Aug 2019; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-000058-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000058-77.